Meeting
2022 ASCO Annual Meeting
Chemotherapy shows better efficacy than endocrine therapy in patients with metastatic breast cancer with heterogeneous estrogen receptor expression.
Authors
Yizhao Xie
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
Yizhao Xie , Xinyue Du , Zhonghua Tao , Yannan Zhao , Chengcheng Gong , Xichun Hu , Zhongyi Yang , Biyun Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1050)
DOI
10.1200/JCO.2022.40.16_suppl.1050
Abstract #
1050
Poster Bd #
428
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Breakthrough
OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for patients with ER+, HER2- advanced or metastatic breast cancer after endocrine therapy and CDK4/6 inhibitors.
First Author: Joohyuk Sohn
Poster
2013 ASCO Annual Meeting
Early prediction of efficacy of endocrine therapy in breast cancer (BC): Pilot study and validation with 18F fluoroestradiol (18F-FES) PET/CT.
First Author: Alessandra Gennari
Poster
2023 ASCO Annual Meeting
Oral elacestrant vs standard-of-care in estrogen receptor-positive, HER2-negative (ER+/HER2-) advanced or metastatic breast cancer (mBC) without detectable ESR1 mutation (EMERALD): Subgroup analysis by prior duration of CDK4/6i plus endocrine therapy (ET).
First Author: Virginia G. Kaklamani
Poster
2023 ASCO Annual Meeting
Lasofoxifene (LAS) plus abemaciclib (Abema) for treating ESR1-mutated ER+/HER2- metastatic breast cancer (mBC) after progression on prior therapies: ELAINE 2 study update.
First Author: Senthil Damodaran